Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review

Overview

Journal Neurol Ther

Publisher Springer

Specialty Neurology

Date 2024 May 14

PMID 38743312

Authors

Elise E Dunning

Boris Decourt

Nasser H Zawia

Holly A Shill

Marwan N Sabbagh

Affiliations

Soon will be listed here.

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder resulting from the deposition of misfolded and neurotoxic forms of tau protein in specific areas of the midbrain, basal ganglia, and cortex. It is one of the most representative forms of tauopathy. PSP presents in several different phenotypic variations and is often accompanied by the development of concurrent neurodegenerative disorders. PSP is universally fatal, and effective disease-modifying therapies for PSP have not yet been identified. Several tau-targeting treatment modalities, including vaccines, monoclonal antibodies, and microtubule-stabilizing agents, have been investigated and have had no efficacy. The need to treat PSP and other tauopathies is critical, and many clinical trials investigating tau-targeted treatments are underway. In this review, the PubMed database was queried to collect information about preclinical and clinical research on PSP treatment. Additionally, the US National Library of Medicine's ClinicalTrials.gov website was queried to identify past and ongoing clinical trials relevant to PSP treatment. This narrative review summarizes our findings regarding these reports, which include potential disease-modifying drug trials, modifiable risk factor management, and symptom treatments.

References

Vaz M, Silvestre S . Alzheimer's disease: Recent treatment strategies. Eur J Pharmacol. 2020; 887:173554. DOI: 10.1016/j.ejphar.2020.173554. View

Rodriguez S, Sahin A, Schrank B, Al-Lawati H, Costantino I, Benz E . Genome-encoded cytoplasmic double-stranded RNAs, found in ALS-FTD brain, propagate neuronal loss. Sci Transl Med. 2021; 13(601). PMC: 8779652. DOI: 10.1126/scitranslmed.aaz4699. View

Dam T, Boxer A, Golbe L, Hoglinger G, Morris H, Litvan I . Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021; 27(8):1451-1457. DOI: 10.1038/s41591-021-01455-x. View

Bowles K, Pugh D, Oja L, Jadow B, Farrell K, Whitney K . Dysregulated coordination of MAPT exon 2 and exon 10 splicing underlies different tau pathologies in PSP and AD. Acta Neuropathol. 2021; 143(2):225-243. PMC: 8809109. DOI: 10.1007/s00401-021-02392-2. View

Giagkou N, Hoglinger G, Stamelou M . Progressive supranuclear palsy. Int Rev Neurobiol. 2019; 149:49-86. DOI: 10.1016/bs.irn.2019.10.013. View

Khanna M, Kovalevich J, Lee V, Trojanowski J, Brunden K . Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement. 2016; 12(10):1051-1065. PMC: 5116305. DOI: 10.1016/j.jalz.2016.06.006. View

Giannopoulos P, Chu J, Sperow M, Li J, Yu W, Kirby L . Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol Psychiatry. 2015; 78(10):693-701. PMC: 4529386. DOI: 10.1016/j.biopsych.2015.01.015. View

Vaswani P, Olsen A . Immunotherapy in progressive supranuclear palsy. Curr Opin Neurol. 2020; 33(4):527-533. PMC: 7722007. DOI: 10.1097/WCO.0000000000000836. View

Di Monte D, Harati Y, Jankovic J, Sandy M, Jewell S, Langston J . Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem. 1994; 62(4):1631-4. DOI: 10.1046/j.1471-4159.1994.62041631.x. View

10.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

11.

Minami S, Min S, Krabbe G, Wang C, Zhou Y, Asgarov R . Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. Nat Med. 2014; 20(10):1157-64. PMC: 4196723. DOI: 10.1038/nm.3672. View

12.

Kim T, Lim H, Lee J, Kim D, Park S, Lee C . Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2008; 436(2):196-200. DOI: 10.1016/j.neulet.2008.03.019. View

13.

Sale P, Stocchi F, Galafate D, De Pandis M, Le Pera D, Sova I . Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report. Front Hum Neurosci. 2014; 8:207. PMC: 4029018. DOI: 10.3389/fnhum.2014.00207. View

14.

Wray S, Saxton M, Anderton B, Hanger D . Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem. 2008; 105(6):2343-52. DOI: 10.1111/j.1471-4159.2008.05321.x. View

15.

Naini S, Soussi-Yanicostas N . Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?. Oxid Med Cell Longev. 2015; 2015:151979. PMC: 4630413. DOI: 10.1155/2015/151979. View

16.

Krug L, Chatterjee N, Borges-Monroy R, Hearn S, Liao W, Morrill K . Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS Genet. 2017; 13(3):e1006635. PMC: 5354250. DOI: 10.1371/journal.pgen.1006635. View

17.

Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E . ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nat Aging. 2023; 1(6):521-534. DOI: 10.1038/s43587-021-00070-2. View

18.

Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S . Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci U S A. 2002; 99 Suppl 4:16400-6. PMC: 139900. DOI: 10.1073/pnas.182426599. View

19.

Boxer A, Qureshi I, Ahlijanian M, Grundman M, Golbe L, Litvan I . Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019; 18(6):549-558. DOI: 10.1016/S1474-4422(19)30139-5. View

20.

Bartolome-Nebreda J, Trabanco A, Velter A, Buijnsters P . O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature. Expert Opin Ther Pat. 2021; 31(12):1117-1154. DOI: 10.1080/13543776.2021.1947242. View